Zheng Quan Ri Bao Wang·2026-01-13 07:46Group 1 - The core viewpoint of the article highlights the launch of a groundbreaking treatment for infantile hemangiomas in China, specifically the gel formulation of Timolol Maleate (brand name: Beimeijing®), which is the first and only approved topical gel for treating "proliferative superficial infantile hemangiomas" globally [1][2] - Beimeijing® was developed by Beijing Melson Pharmaceutical Technology Co., Ltd. over a span of twelve years, marking a significant advancement in the treatment of this condition, transitioning China from a follower to a leader in this medical field [1][2] - The product was officially launched on Alibaba Health, allowing parents to access the treatment through an online consultation, thus enhancing the accessibility and convenience of care for families [1][3] Group 2 - The drug received approval from the National Medical Products Administration (NMPA) on September 30, 2025, and has been recognized by the national drug pricing management system, establishing a traceable and referenceable price benchmark for Chinese original drugs in the international market [1][2] - The clinical consensus emphasizes the importance of intervention during the "golden window period" of 1-6 months after birth, as untreated hemangiomas can lead to permanent skin issues, highlighting the need for effective treatment options [2] - The gel formulation allows for localized application, significantly reducing systemic exposure risks and enhancing safety for infants, compared to traditional treatments such as oral medications or surgical interventions [2][3] Group 3 - Phase III clinical trial data supports the efficacy and safety of Beimeijing®, showing a clinical cure rate of 60.7% and an overall effective rate of 89.4% among 121 infants aged 1-6 months [3] - Alibaba Health aims to create a comprehensive service ecosystem centered around the child, facilitating the delivery of standardized treatment solutions and long-term management for families in need [3]